Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cabometyx

How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy

Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests...

Research Partnership

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

Research Partnership

Bristol-Myers Squibb (BMS) building

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

- PMLiVE

Shire offloads oncology unit to Servier for $2.4bn

The French drugmaker will also acquire Oncaspar and Onivyde as part of the deal

- PMLiVE

Beyond caring: learning from the unsung advocates in cancer care

Macmillan Cancer Support estimates that there are currently around 1.5 million carers caring for someone who has cancer in the UK. Broadly, carers in and outside cancer contribute around £132...

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

- PMLiVE

Ipsen bolsters leadership team

Ivana Magovcevic-Liebisch and Régis Mulot join the biopharma

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led...

Research Partnership

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

Research conducted by Research Partnership published in leading medical journal

Findings from a study conducted by Research Partnership have recently been published in the ‘Supportive Care in Cancer’ journal

Research Partnership

Bristol-Myers Squibb (BMS) building

BMS gets OK for monthly Opdivo dosing

Analysts predict the new dosing schedule could see the pharma giant win market share

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links